Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 


Nanomedicine Award: winners of the best international nanomedicine innovation 2013

Since the official launch in June 2013, the European Technology Platform for Nanomedicine (ETPN) together with the EU funded consortium NANOMED2020, are organising the first ever Nanomedicine Award to honor the best international nanomedicine innovation for 2013!

The call for applications ended on September 7th gathering overall 23 candidatures coming from all over the world: from Europe but also from Australia and the US. Gathering academia and SMEs, and covering all three fields of diagnostics and imaging, therapeutics and regenerative medicine, this first edition is seen as a success holding great promises for the coming years.

The Award winners will be officially announced during the Nanomedicine Panel Session at BIO-Europe® 2103 in Vienna on 4th November. Projects have since been reviewed and assessed by a panel of highly-qualified pharma industry specialists with experience in R&D and commercial roles: Laurent Levy, Nanobiotix; Neil Desai, Celgene; Mike Eaton, consultant; Patrick Tricoli, Sanofi; Karen Zinkevich-Peotti, Ipsen and Thorsten Melcher, Johnson & Johnson Innovation.

For the second time at BIO-Europe, a session is especially dedicated to the field of nanomedicine, representing a major opportunity to increase the visibility and synergies of the field with the pharmaceutical industries, a crucial stakeholder in the development of nanotherapeutics towards the patients.

The winners will receive media coverage across Europe and gain visibility to EU decision makers from biotechnology, pharma, academia and finance. Winners will also benefit from a full registration (including partnering) for BIO-Europe 2013 and a 5-minute presentation slot at the Nanomedicine Panel Discussion during the event. In addition, the winning project will also be granted a 15-minute presentation slot during the CLINAM conference 2014 in Basel, Switzerland, along with 1 year’s free ETPN membership and two days consultation by the members of the ETPN Translational Advisory Board.

ABOUT ETP Nanomedicine - www.etp‐
The European Technology Platform Nanomedicine was established in 2005 as a joint venture of the European Commission and CEOs of large industrial companies, SMEs and academic research institutions to investigate and advance joint activities in the area of nanotechnology in medicine. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe. The ETPN contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicine. The ETPN supports its members in coordinating their joint research efforts and improving communication amongst the members as well as towards the European Commission and the European Member States.
The 19th annual BIO-Europe® event will be the largest biotechnology partnering conference held in Europe. Over 3,000 global decision makers from biotechnology, pharma and finance, representing upwards of 1,700 companies from over 50 countries, annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe will take place November 4–6, 2013 in Vienna, Austria.

Follow BIO-Europe 2013 on Twitter: (hashtag: #BEU13)


Nanobiotix -
Nanobiotix is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy and brachytherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration. Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and for Head and Neck cancers. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the NYSE Euronext regulated market in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

EBD Group-
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America™, the fastest growing partnering event in North America
- Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry
- Partnering for Global Impact®, a new partnering conference providing an innovative forum to partner, identify and generate social and philanthropic investment and funding opportunities

EBD Group’s sophisticated web-based partnering service, partneringONE®, is also used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences all year long.

EBD Group has offices in the USA and Europe.

For more information please visit
Erin Righetti
EBD Group
+1 760 930 0500
ETPN Secretariat c/o VDI/VDE Innovation + Technik GmbH
Olivier Fontaine
+49 (0)30 310078 155

Wiebke Ehret | idw
Weitere Informationen:

Weitere Nachrichten aus der Kategorie Förderungen Preise:

nachricht Furchtlos durch die virtuelle Welt – MRT-Datenbrille
19.10.2016 | Universität Duisburg-Essen

nachricht Bochumer Wissenschaftlerin erforscht Bedeutung der Mikrogliazellen für das Glaukom
18.10.2016 | Ruhr-Universität Bochum

Alle Nachrichten aus der Kategorie: Förderungen Preise >>>

Die aktuellsten Pressemeldungen zum Suchbegriff Innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Mikrostrukturen mit dem Laser ätzen

Mit dem Ultrakurzpulslaser lassen sich nicht nur feine Strukturen schneiden, in einem Verbundprojekt haben Wissenschaftler untersucht, wie man damit auch Mikrostrukturen in Dünnglas erzeugen kann. Anwendungen gibt es im Analytikbereich (lab-on-a-chip), aber auch in der Elektronikbranche und im Consumer-Bereich gibt es großes Interesse.

Am Anfang dieser neuen Methode stand ein überraschender Effekt: Wenn Glas mit dem Ultrakurzpulslaser in der richtigen Weise bestrahlt wird, wird es so...

Im Focus: Etching Microstructures with Lasers

Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.

This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...

Im Focus: Tarnkappe aus Nanostrukturen

Linsen, Objektive, Brillengläser oder auch Laser sind in der Regel mit einer Antireflexschicht versehen. Solche Schichten haben oft den Nachteil, dass sie nur innerhalb enger Wellenlängenbereiche optimal wirksam sind. Forscher des Max-Planck-Instituts für Intelligente Systeme in Stuttgart stellen nun eine alternative Technologie vor. Anstatt eine Beschichtung aufzubringen, bearbeiten sie die Oberfläche selbst. Im Vergleich zu herkömmlichen Verfahren können sie so den gewünschten Effekt über einen größeren Wellenlängenbereich erzielen, und das bei besonders großer Lichtdurchlässigkeit.

Der Nachtfalter macht es vor. Seine Augenoberflächen sind so beschaffen, dass sie einfallendes Licht praktisch nicht reflektieren. Keine Lichtreflexe – das...

Im Focus: Lichtinduzierte Rotationen von Atomen rufen Magnetwellen hervor

Terahertz-Anregung ausgewählter Kristallschwingungen führt zu einem effektiven Magnetfeld, das kohärente Spindynamik antreibt

Die Kontrolle funktionaler Eigenschaften durch Licht ist eines der großen Ziele moderner Festkörperphysik und der Materialwissenschaften. Eine neue Studie...

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Alle Focus-News des Innovations-reports >>>



im innovations-report
in Kooperation mit academics

Science or Fiction? MHH-Forscher beleuchten Stammzellforschung

25.10.2016 | Veranstaltungen

BAM und Bildungswerk VDV laden zur Fachtagung „Messen im Bauwesen“ am 08.11.2016

25.10.2016 | Veranstaltungen

Internationale Forscher-Elite sucht Lösungen zur Rettung des Feldhamsters

25.10.2016 | Veranstaltungen

Weitere VideoLinks >>>
Aktuelle Beiträge

Mikrostrukturen mit dem Laser ätzen

25.10.2016 | Verfahrenstechnologie

Wussten Sie, dass Infrarot-Wärme in der modernen Automobilproduktion unverzichtbar ist?

25.10.2016 | Energie und Elektrotechnik

Metallfreier Katalysator spaltet Wasserstoffmolekül

25.10.2016 | Biowissenschaften Chemie